Journal of Hepatology
Volume 53, Issue 2 , Pages 238-244 , August 2010

Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection

  • Paul Calès

      Affiliations

    • Hepatology Department, University Hospital, Angers, France
    • HIFIH Laboratory, UPRES 3859, IFR 132, Angers University, PRES UNAM, France
    • Corresponding Author InformationCorresponding author. Present address: Service d’Hépato-Gastroentérologie, CHU, 49933 Angers Cedex 09, France. Tel.: +33 2 41 35 34 10; fax: +33 2 41 35 41 19.
    • ,
  • Philippe Halfon

      Affiliations

    • Alphabio Laboratory, Marseilles, France
    • ,
  • Dominique Batisse

      Affiliations

    • Immunology Department, Hôpital Européen Georges Pompidou, Paris, France
    • ,
  • Fabrice Carrat

      Affiliations

    • INSERM, Unité de Recherche en Épidémiologie Systèmes d’Information et Modélisation (U707), Paris, F-75012, France
    • UPMC-Paris6, Faculté de Médecine Pierre et Marie Curie, UMR-S707, Paris, F-75012, France
    • Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, F-75012, France
    • ,
  • Philippe Perré

      Affiliations

    • Internal Medicine Department, CHG, La Roche/Yon, France
    • ,
  • Guillaume Penaranda

      Affiliations

    • Alphabio Laboratory, Marseilles, France
    • ,
  • Dominique Guyader

      Affiliations

    • Hepatology Department, University Hospital, Rennes, France
    • ,
  • Louis d’Alteroche

      Affiliations

    • Hepatology Department, University Hospital, Tours, France
    • ,
  • Isabelle Fouchard-Hubert

      Affiliations

    • Hepatology Department, University Hospital, Angers, France
    • HIFIH Laboratory, UPRES 3859, IFR 132, Angers University, PRES UNAM, France
    • ,
  • Christian Michelet

      Affiliations

    • Infectious Diseases Department, University Hospital, Rennes, France
    • ,
  • Pascal Veillon

      Affiliations

    • Hepatology Department, University Hospital, Angers, France
    • HIFIH Laboratory, UPRES 3859, IFR 132, Angers University, PRES UNAM, France
    • ,
  • Jérôme Lambert

      Affiliations

    • INSERM, Unité de Recherche en Épidémiologie Systèmes d’Information et Modélisation (U707), Paris, F-75012, France
    • UPMC-Paris6, Faculté de Médecine Pierre et Marie Curie, UMR-S707, Paris, F-75012, France
    • Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, F-75012, France
    • ,
  • Laurence Weiss

      Affiliations

    • Immunology Department, Hôpital Européen Georges Pompidou, Paris, France
    • Hepatology Department, University Hospital, Tours, France
    • ,
  • Dominique Salmon

      Affiliations

    • Université Paris Descartes, Faculté de Médecine, Paris, France
    • Infectious Diseases, Internal Medicine Department, Hôpital Cochin, Paris, France
    • ,
  • Patrice Cacoub

      Affiliations

    • Department of Internal Medicine, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
    • Pierre and Marie Curie (Paris 6) University, CNRS UMR7087, Paris, France

Received 8 October 2009 ,Revised 13 March 2010 ,Accepted 17 March 2010.

References 

  1. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9:82–88
  2. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50:165–173
  3. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373–1381
  4. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol. 2005;43:78–84
  5. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325
  6. Nunes D, Fleming C, Offner G, O’Brien M, Tumilty S, Fix O, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr. 2005;40:538–544
  7. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41:175–179
  8. Tural C, Tor J, Sanvisens A, Perez-Alvarez N, Martinez E, Ojanguren I, et al. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol. 2009;7:339–345
  9. Loko MA, Castera L, Dabis F, Le Bail B, Winnock M, Coureau G, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV–HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol. 2008;103:1973–1980
  10. Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, Sampaio JP, Lanzoni VP, Ferraz ML. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver Int. 2008;28:486–493
  11. Al-Mohri H, Cooper C, Murphy T. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med. 2005;6:375–378
  12. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. Aids. 2003;17:721–725
  13. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, Merino D, Cano P, Mira JA, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut. 2006;55:409–414
  14. Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Perronne C, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02. J Hepatol. 2008;48:765–773
  15. Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials. 2008;9:43–51
  16. Michel L, Villes V, Dabis F, Spire B, Winnock M, Loko MA, et al. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV–HCV co-infected patients: ANRS Co13 Hepavih, France, 2006–2008. J Viral Hepat. 2009;[Epub ahead of print]
  17. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867–1873
  18. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526
  19. Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem. 2008;41:1368–1376
  20. Cales P, Veillon P, Konate A, Mathieu E, Ternisien C, Chevailler A, et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem. 2008;41:10–18
  21. The French METAVIR Cooperative Study Group . Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20
  22. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:395–402
  23. Cales P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008;28:1352–1362
  24. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49:7–18
  25. Parkes J, Guha IN, Roderick P. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44:462–474
  26. Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem. 2008;54:1372–1378
  27. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids. 2008;22:1979–1991
  28. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41:257–264
  29. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–569
  30. Reiss G, Keeffe EB. Role of liver biopsy in the management of chronic liver disease: selective rather than routine. Rev Gastroenterol Disord. 2005;5:195–205
  31. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. Aids. 2007;21:2209–2216
  32. Elion R, Cohen C, Ward D, Ruane P, Ortiz R, Reddy YS, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials. 2008;9:213–224
  33. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655

PII: S0168-8278(10)00271-0

doi: 10.1016/j.jhep.2010.03.007

Journal of Hepatology
Volume 53, Issue 2 , Pages 238-244 , August 2010

Article Tools

* Image Usage & Resolution